Teva, Maker of Generic Drugs, Bids $40 Billion to Acquire Its Rival Mylan - The New York Times
Teva makes $40 billion offer for Mylan
Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid | Reuters
How Mylan tried to keep Teva from selling a generic EpiPen
Drugmaker Teva makes $40B bid for rival Mylan
Mylan, Generic Copaxone Punish Teva (NYSE:TEVA) | Seeking Alpha
Mylan surges, Teva slumps after FDA approves Copaxone copy | Reuters.com
Teva, Mylan to jumpstart production of old malaria drug to fight coronavirus
Mylan rejects Teva takeover bid as too low | Mint
Federal Circuit Upholds Mylan's U.S. Patents on Perforomist® Inhalation Solution; Decision Prevents Approval of Teva ANDA
Teva Offers to acquire Mylan for $40 billion in cash, stock | Pharma Companies
Teva launches generic EpiPen in the U.S. | Fierce Biotech
Teva shares rival Mylan's pain as both hit two-year lows | Fierce Pharma
Teva's Generic EpiPen Will Cost As Much As Mylan's Generic | Time
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Teva or Mylan: Who Has the More Promising Revenue Trajectory?
Teva Offers to Buy Mylan for $40 Billion - WSJ
FDA swats down Teva's EpiPen copy, putting Mylan in cruise control | Fierce Pharma
Teva, Mylan, Sandoz and Aurobindo hit with patent suit
Teva's Deal for Mylan Shows Corporate Israel's M&A Hunger - WSJ
$40B deal: Teva offers to buy Mylan
Where a Teva-Mylan Deal Would Rank Among Big Pharma Companies
